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Individuals diagnosed with schizophrenia have an exceptionally high risk for tobacco dependence. Postmortem studies show that these
individuals have significant reductions in a7 nicotinic acetylcholine receptors (nAChRs) in several brain areas. Decreased a7-mediated
function might not only be linked to schizophrenia but also to increased tobacco consumption. The purpose of this study was to
determine whether pharmacological blockade of a7 nAChRs would increase motivation of rats to intravenously self-administer nicotine
(NIC) during a progressive ratio schedule of reinforcement (PR). Before PR, rats received local infusions of 0, 10, or 20pmol of a selective
a7 nAChR antagonist, a-conotoxin ArIB [V11L,V16D] (ArIB) into the nucleus accumbens (NAc) shell or the anterior cingulate cortex,
brain areas that contribute to motivation for drug reward. We additionally sought to determine whether local infusion of 0, 10, or
40nmol of a selective a7 nAChR agonist, PNU 282987, into these brain areas would decrease motivation for NIC use. Infusion of ArIB
into the NAc shell and anterior cingulate cortex resulted in a significant increase in active lever pressing, breakpoints, and NIC intake,
suggesting that a decrease in a7 nAChR function increases motivation to work for NIC. In contrast, PNU 282987 infusion resulted in
reductions in these measures when administered into the NAc shell, but had no effect after administration into the anterior cingulate
cortex. These data identify reduction of a7 nAChR function as a potential mechanism for elevated tobacco use in schizophrenia and also
identify activation of a7 nAChRs as a potential strategy for tobacco cessation therapy.
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INTRODUCTION
Individuals with schizophrenia have a high risk for tobacco
dependence. Epidemiological studies estimate that as many
as 80% of individuals diagnosed with schizophrenia smoke
cigarettes and clinical reports indicate that those with
schizophrenia are particularly heavy smokers (Hughes et al,
1986; Glassman, 1993; Olincy et al, 1997; Kalman et al, 2005;
Tidey et al, 2005; Williams et al, 2005, 2007; McKee et al,
2009). In support of a self-medication hypothesis, some
studies have shown that smoking enhances cognition,
improves sensory-gating deficits, and relieves side effects
of neuroleptic therapeutics (Leonard et al, 1998, 2007; Sacco
et al, 2005; Levin and Rezvani, 2007; D’Souza and Markou,
2011). Another equally plausible hypothesis is that these
individuals have a shared vulnerability for schizophrenia
and tobacco dependence.
An accumulation of genetic reports have identified
polymorphisms linked to the a7 nicotinic acetylcholine
receptor (nAChR) gene with diagnosis of schizophrenia
(Leonard et al, 1996; Freedman et al, 1997; Stassen et al,
2000; Stephens et al, 2009; Mexal et al, 2010). Recent reports
suggest that genetic variations in CHRNA7 may be
associated with tobacco dependence as well (De Luca
et al, 2004; Saccone et al, 2010). Nicotine (NIC), a major
psychoactive ingredient in tobacco, binds to these ion
channel receptors that are activated endogenously by the
neurotransmitter, acetylcholine (ACh). Postmortem studies
indicate that individuals with schizophrenia have marked
reductions of a7 nAChRs in several brain areas, including
the hippocampus and cingulate cortex (Freedman et al,
1995; Leonard et al, 1996, 1998, 2000; Guan et al, 1999;
Court et al, 2000; Marutle et al, 2001; Mexal et al, 2010).
Several CHRNA7 polymorphisms may contribute to a
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et al, 2010), and independent data sets have revealed
CHRNA7 polymorphisms associated with increased vulner-
ability for a tobacco dependence phenotype in those
with schizophrenia diagnosis (De Luca et al, 2004). a7
Polymorphisms are linked to sensory-gating deficits
(Freedman et al, 1997), a phenomenon commonly observed
with schizophrenia diagnosis. Rodent studies have indicated
that sensory-gating deficits may be due to a reduction in a7
nAChR function (Luntz-Leybman et al, 1992; Stevens et al,
1996, 1998; Hajos et al, 2005). Although no studies to date
have correlated genetic analyses with a7 nAChR expression
in humans, in vitro studies show that point mutations in the
CHRNA7 promoter region and in an a7-duplicated gene is
sufficient to alter a7 nAChR function (Leonard et al, 2002;
Araud et al, 2011; de Lucas-Cerrillo et al, 2011).
The purpose of this preclinical study was to determine
whether reductions of the a7 nAChR function constitute a
biological mechanism for increased motivation for tobacco
use as measured using a progressive ratio schedule of
reinforcement (PR) during NIC self-administration in rats.
Rats, like humans, readily self-administer NIC and there is
93% sequence homology in the rat and human a7 nAChRs
(as determined using the Basic Local Alignment Search Tool
for accession numbers AAB25224-rat and AAB40114-
human) (Se ´gue ´la et al, 1993; Elliott et al, 1996). During
PR, rats must work increasingly hard for a single delivery of
NIC until they give up responding (ie, reach their break-
point). We tested the hypothesis that reduced activity of a7
nAChRs in areas that regulate motivation for drug use
would result in an increase in active lever pressing for NIC
and breakpoints during PR. Such an effect might contribute
to increased tobacco addiction in those with schizophrenia.
The selective a7 nAChR antagonist, a-conotoxin ArIB
[V11L,V16D] (ArIB) (Whiteaker et al, 2007) was infused
into the nucleus accumbens (NAc) shell or anterior
cingulate cortex immediately before PR. This study also
questioned whether local infusion of a selective agonist of
a7 nAChRs, PNU 282987 (Bodnar et al, 2005), into the NAc
shell and anterior cingulate cortex would lead to reductions
in responding maintained by NIC during PR. The a7
agonists are currently being explored as therapeutics to
improve cognition, working memory, and sensory-gating
deficits in schizophrenia (Bodnar et al, 2005; Olincy et al,
2006; Bitner et al, 2007; Freedman et al, 2008; Rezvani et al,
2009; Thomsen et al, 2009; Hajos and Rogers, 2010; Castner
et al, 2011; Marquis et al, 2011). A positive finding would
have implications for smoking cessation therapies in
general.
MATERIALS AND METHODS
Animals
A total of 34, adult, male, Long-Evans rats (Harlan
Laboratories, Dublin, VA) were used for these studies. Rats
were individually housed in a temperature- and humidity-
controlled vivarium under a 12/12h light/dark cycle (lights
on at 0600 hours). Behavioral testing took place between
1300 and 1900 hours. Rats weighed B300g upon arrival and
began testing at 320g. This body weight was maintained
by daily food rations throughout behavioral testing.
Experimental protocols were approved by the Institutional
Animal Care and Use Committee at the Virginia Common-
wealth University and were in accordance with the Guide-
lines for the Care and Use of Laboratory Animals, as set
forth by the National Institutes of Health.
Drug Dosing and Administration
During self-administration procedures, rats received
0.03mg/kg/i.v. infusion of NIC (by weight of freebase) in
0.0533ml delivered over 1s. NIC hydrogen tartrate salt was
dissolved in 0.9% sterile saline and stored in the dark to
prevent degradation. a-CTX ArIB [V11L,V16D] was synthe-
sized as described previously (Whiteaker et al, 2007)
(Institute for Behavioral Genetics, Boulder, CO) and
dissolved in 0.9% sterile saline. PNU 282987 was obtained
commercially (Tocris, Ellisville, MO) and dissolved accord-
ing to the supplier’s recommendations in 100mM HCl
sterile saline. Aliquots were stored at  201C and thawed
immediately before use. Immediately before PR testing,
intra-accumbens shell or intra-anterior cingulate infusions
of 0, 10, or 20pmol/hemisphere of ArIB, or 0, 10 or 40nmol/
hemisphere PNU 282987 were administered at a volume of
0.5–1.0ml at a rate no greater than 0.5ml/min using a
within-subject, Latin-square design across days. Vehicle
infusions were administered intermittently to assure drug
clearance. Animals either received infusions into the
anterior cingulate cortex or the NAc, and separate animals
were used in experiments that assessed the effects of a7
nAChR antagonist and agonist.
Intra-Cranial Guide Cannula Implantations
All surgeries were performed using aseptic procedures
under isoflurane anesthesia (induced at 3.5l/min of oxygen
and 3.5% isoflurane gas and maintained at B2.5l/min of
oxygen and 2.0–2.75% isoflurane). During surgery, rats
received 5mg/kg i.p. carprofen for preemptive analgesia.
Surgical areas were shaved and cleaned with 7.5%
povidone-iodine and 70% reagent alcohol. Rats were placed
in a stereotaxic device with the bregma and lambda leveled
to within 0.05mm. Animals were implanted with 22-G
bilateral guide cannula (Plastics One, Roanoke, VA)
targeting either the NAc shell (+1.6mm anterior,
±0.75mm from midline,  6.5mm ventral from the
bregma) or the anterior cingulate cortex (+1.8 anterior,
±0.75 from midline,  2.75 ventral from the bregma). Guide
cannulae were held in place with dental cement anchored
with jeweler’s screws, and dummy cannulae were inserted
into the guides to maintain patency. Rats received 64mg
acetaminophen mixed in wet chow for 3 days after surgery.
After behavioral procedures, brains were harvested to assess
cannulae placement.
Intra-Jugular Catheter Implantation
Animals were anesthetized, prepped for surgery, and
received analgesia as described above. A polyurethane
catheter (3.5 French, Access Technologies) was implanted in
the right jugular vein above the atrium and passed
subcutaneously to the rat’s back where it was connected
to a cannula connector pedestal (Plastics One) implanted
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received s.c. injection of 75000Units of penicillin G and
0.1ml intra-catheter injection of 0.031mg/ml ticarcillin/
clavulanate in a 25% glycerol/heparinized saline solution
(catheter lock). Rats were allowed to recover for at least
5 days before self-administration training. Before and after
training sessions, catheters were irrigated with 0.9% sterile
saline. Catheter patency was defined as a rapid loss of
consciousness after 1.6mg i.v. ketamine infusion. In the
case of catheter failure, the left jugular vein was catheterized
and the animal was returned to the study.
NIC Self-Administration
Self-administration procedures were as described pre-
viously (Brunzell et al, 2010). All self-administration
procedures occurred in MED Associates operant chambers
located within sound-attenuating boxes (St Albans, VT).
Rats were tethered to a stainless steel-encased infusion
tubing that was suspended from the chamber ceiling
(Plastics One) to enable them to move freely about the
chamber during each 2h self-administration session. Levers
were extended and a 5-w house light remained illuminated
during all behavioral procedures. For a period of at least 10
days, rats were reinforced under a fixed ratio 1 (FR1)
schedule of reinforcement maintained by NIC. NIC infu-
sions were delivered using a Model PHS-100 syringe pump
located on the outside of each sound-attenuating box. A
panel light above the active (right-side) lever and a Sonalert
tone generator at the rear of the chamber operated as cues.
For NIC rats, depression of the ‘active’ lever resulted in
delivery of a 1s, 0.03mg/kg/i.v. NIC bolus plus a 20s light+
tone. No further NIC was delivered during this time-out
period. To control for potential locomotor effects of the a7
nAChR ligands and for the primary reinforcing properties
of the cues, a separate group of rats received the same cues
without NIC infusion upon depression of the active lever
(CUEonly). Depressions of the ‘inactive’ left lever were
recorded but were without scheduled consequences for NIC
and CUEonly rats. Rats were trained for at least 10 days and
until they reached a criterion of 3 consecutive days of
470% active:total lever presses. Behavioral programs and
data collection were controlled by MED-PC IV software
(MED Associates).
PR Responding Maintained by NIC
After FR training, rats were reinforced using a PR schedule.
This phase of training required that rats depress the lever an
increasing number of times to obtain a single NIC infusion
and/or cue reinforcement (eg, 1, 2, 4, 6, 9, 12, 15, 20, 25, 32,
40, 50, 62, 77, 95) (Arnold and Roberts, 1997). Sessions
lasted for 2h or until a rat failed to respond for 20
consecutive minutes. Active and inactive lever responses,
number of infusions, and the highest lever depression
criterion achieved (breakpoint) were recorded.
Local Infusions of a7 Agonists and Antagonists
into the Anterior Cingulate and NAc Shell
Rats received 2–3 days of 0.9% sterile saline infusions and
intermittent infusions of vehicle to assure a stable level of
PR responding. Independent groups of rats received daily
infusions of either ArIB (0, 10, 20pmol/hemisphere; n¼18)
or PNU 282987 (0, 10, 40nmol/hemisphere; n¼16) using a
within-subject, Latin-square counterbalanced delivery of
doses. Implanted guide cannulae targeting the NAc shell or
anterior cingulate cortex assured that ligands did not diffuse
to brain areas dorsal to the desired brain regions (Brunzell
et al, 2009, 2010). Infusions were made using a micro
infusion pump with Hamilton syringes attached to PE 20
tubing (Braintree Scientific, Braintree, MA). Infusion
volumes were no greater than 1ml and were delivered at a
rate no faster than 0.5ml/min through internal cannulae that
extended 0.5mm beyond the guides. Infusions were
followed by a 2min wait period to allow for drug diffusion
and to prevent backflow of ArIB or PNU 282987 through the
guide cannula.
Statistical Analysis
Within-subject, repeated-measures ANOVAs were used to
analyze effects of vehicle and various concentrations of ArIB
or PNU 282987 on behavioral measures for NIC and CUE-
only rats during PR. Significant interactions of NIC
condition with drug infusion were followed up with post
hoc t-tests that compared behavioral data after drug
infusion to data collected after infusion of vehicle into the
brain areas studied.
RESULTS
Antagonism of NAc shell a7 nAChRs resulted in a dose-
dependent increase in motivation to self-administer NIC
(Figure 1). There was a significant interaction of NIC
condition with the ArIB dose for measures of breakpoint
(F1,7¼8.26, p¼0.02) and active lever pressing (F1,7¼9.56,
p¼0.02) revealing that this effect was specific to NIC
animals. There were main effects of NIC treatment
(F1,7¼92.077, po0.01) and ArIB dosage (F1,7¼5.53,
p¼0.05) for infusions/CUE presentations earned, but the
interaction of these factors failed to reach significance. Post
hoc t-tests showed that the 20pmol/hemisphere infusion led
to significant increases in how hard animals were willing to
work for NIC (Figure 1a and b) and in the amount of NIC
infusions earned (Table 1) (p’s o0.05). Previous studies
have shown that rodents will press for a visual stimulus
reinforcer and that this behavior, like drug reinforcement, is
dopamine mediated (Caggiula et al, 2002; Olsen and
Winder, 2009). Infusion of ArIB into the NAc shell had no
effect on lever pressing or breakpoints in CUEonly rats,
suggesting that this effect did not generalize to other
reinforcers. There was also no effect of drug exposure on
response accuracy (active lever presses/(active+inactive
lever presses)) after infusions of ArIB into the NAc shell
(Fo1.0); response accuracy remained high regardless of
ArIB dose (Figure 1c), indicating that ArIB-associated
increases in lever pressing were directed toward the lever
that was reinforced with NIC infusions and not due to a
non-specific increase in lever pressing activity.
Antagonism of a7 nAChRs in the anterior cingulate cortex
of an independent group of rats resulted in similar increases
in motivation to self-administer NIC. There was a
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breakpoint (F1,8¼10.77, p¼0.01) and active lever pressing
(F1,8¼8.53, p¼0.02) and NIC infusions/CUE presentations
(F1,8¼18.71, po0.01). In comparison to vehicle infusion,
local infusion of 10 or 20pmol/hemisphere of ArIB into the
anterior cingulate cortex led to a significant increase in
active lever pressing, breakpoints (Figure 2a and b), and
NIC/CUE delivery (Table 1) in NIC (p’s o0.05) but not
CUEonly subjects. As with the NAc shell, there was no effect
of ArIB infusion into the anterior cingulate on response
accuracy (Figure 2c, Fo1.0), suggesting that a7n A C h R si n
this region do not modulate non-specific lever pressing
activity or motivation to work for cue reinforcement. These
findings support the hypothesis that reductions of the a7
nAChR function in the NAc shell and anterior cingulate
cortex significantly increase motivation for NIC use.
The next series of experiments tested whether activation
of a7 nAChRs in these brain regions would attenuate
responding maintained by NIC during PR. Local infusion of
the selective a7 nAChR agonist PNU 282987 into the NAc
shell resulted in a significant interaction of NIC condition
and drug dosage for breakpoint (F1,6¼13.80, p¼0.01) for
active lever pressing (F1,6¼33.19, po0.01) and number of
infusions/CUE presentations attained (F1,6¼6.82, p¼0.04).
In contrast to increases in active lever presses and
breakpoints observed in rats after antagonism of the NAc
shell a7 nAChRs, rats that received local activation of these
nAChRs through infusion of PNU 282987 showed reduc-
tions in active lever presses and breakpoints during PR
(Figure 3). NIC rats showed a significant reduction in active
lever presses and breakpoints after intra-accumbens shell
infusion of 10 or 40nmol/hemisphere of the PNU
compound (p’s o0.05). As before, this effect was specific
to NIC rats and not observed in CUEonly animals. There
was also no effect of NIC condition or drug infusion on
response accuracy (Fo1.0).
In contrast to pretreatment with the a7 antagonist,
ArIB, effects of PNU 282987 were specific to the NAc
shell. There was no interaction of NIC condition with PNU
282987 concentration observed for measures of break-
point, active lever presses, or number of NIC infusions
(Fo1.0) after anterior cingulate infusion of this selective
Figure 1 Antagonism of a7 nAChRs in the NAc shell increases
motivation to self-administer nicotine. Local NAc shell infusion of ArIB
led to a dose-dependent increase in (a) breakpoints and (b) active lever
pressing maintained by nicotine during a progressive ratio schedule of
reinforcement (NIC; n¼4). There was no effect of ArIB infusion on
breakpoint or active lever pressing in rats reinforced with light+tone cues
but no nicotine (CUEonly; n¼4). (c) Response accuracy as measured by %
active lever pressing was not affected by NAc shell infusion of ArIB in NIC
or CUEonly rats. *Significantly different from NIC vehicle infusion
(po0.05).
Table 1 Nicotine Intake after NAc Shell or Anterior Cingulate Infusion of a7 nAChR Antagonist or Agonist
a-Conotoxin ArIB [V11L, V16D] PNU 282987
pmol/hemisphere: 0 10 20 0 10 40
NAc shell Nicotine infusions 7.4±0.92 9.4±0.75
a 10.20±0.37
a 7.0±0.41 2.75±0.63
a 4.0±1.22
a
Intake mg/kg 0.21±0.03 0.31±0.02
a 0.34±0.01
a 0.23±0.01 0.09±0.02
a 0.13±0.04
a
Anterior cingulate cortex Nicotine infusions 5.2±1.02 8.4±1.17
a 8.2±1.16
a 5.8±0.74 5.4±0.97 5.75±1.49
Intake mg/kg 0.16±0.03 0.25±0.03
a 0.25±0.03
a 0.19±0.03 0.16±0.03 0.23±0.03
Number of i.v. nicotine infusions and total nicotine intake achieved during a progressive ratio schedule of reinforcement after local infusion of either a-conotoxin ArIB
[V11L, V16D] (0, 10, or 40 pmol/hemisphere) or PNU 282987 (0, 10, or 40nmol/hemisphere) into the nucleus accumbens (NAc) shell or into the anterior cingulate
cortex of rats. Antagonism of a7 nicotinic acetylcholine receptors (nAChRs) with a-conotoxin ArIB[V11L, V16D] resulted in a significant increase in nicotine intake
when administered into the NAc shell or the anterior cingulate cortex. In contrast, local infusion of an agonist of nAChRs,
PNU 282987, led to significant decreases in nicotine intake, but only when administered into the NAc shell.
aIndicates significantly different from vehicle infusion (po0.05; n¼4–5 per group).
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infusion and not due to behavioral variation between
NAc shell- and anterior cingulate-infused rats. On the
last day of FR1 before PR testing, NIC rats earned a similar
number of NIC infusions regardless of whether they had
cannulae implanted into the NAc shell (mean¼20.57±
3.03) or the anterior cingulate cortex (mean¼20.13±3.35).
Rats also showed similar levels of NIC intake when
infused with vehicle during PR (Table 1). Neuroanatomical
reconstructions of guide cannula placement are shown in
Figure 4.
DISCUSSION
This study provides functional evidence that reductions in
a7 nAChR activity support motivation for NIC self-
administration. Selective antagonism of a7 nAChRs sig-
nificantly increased the impetus of rats to work for NIC
during PR. This effect was observed after drug infusion into
the NAc shell, a brain area well-known for its contributions
to motivational valence for drugs and natural rewards, as
well as after antagonist infusion into the anterior cingulate
cortex, a brain area that contributes to addiction, supports
behavioral inhibition, and is morphologically compromised
in individuals with schizophrenia (Goldman-Rakic, 1994;
Guan et al, 1999; Chambers et al, 2001; Marutle et al, 2001;
Moss et al, 2009). In contrast, local infusion of a selective a7
nAChR agonist into the NAc shell significantly reduced how
hard rats were willing to work for a single infusion of NIC,
suggesting that activation of these receptors may promote
tobacco cessation. This effect was specific to the NAc shell
and not observed in the anterior cingulate cortex. These
data suggest that a7 nAChRs are not required for NIC
self-administration but rather have a critical role in
modulating NIC use.
Together with genetic and postmortem human studies
(Freedman et al, 1995, 1997; Guan et al, 1999; Marutle et al,
Figure 2 Antagonism of a7 nAChRs in the anterior cingulate cortex
increases motivation to self-administer nicotine. Local anterior cingulate
infusion of ArIB led to an increase in (a) breakpoints and (b) active lever
pressing maintained by nicotine during a progressive ratio schedule of
reinforcement (NIC; n¼5). There was no effect of ArIB infusion on
breakpoint or active lever pressing in rats reinforced with light+tone cues
but no nicotine (CUEonly; n¼5). (c) Response accuracy as measured by %
active lever pressing was not affected by anterior cingulate infusion of ArIB
in NIC or CUEonly rats. *Significantly different from NIC vehicle infusion
(po0.05).
Figure 3 Agonism of a7 nAChRs in the NAc shell decreases motivation
to self-administer nicotine. Local NAc shell infusion of PNU 282987 led to
a significant decrease in (a) breakpoints and (b) active lever pressing
maintained by nicotine during a progressive ratio schedule of reinforcement
(NIC; n¼4). There was no effect of PNU 282987 infusion on breakpoint
or active lever pressing in rats reinforced with light+tone cues but no
nicotine (CUEonly; n¼4). (c) Response accuracy as measured by % active
lever pressing was not affected by NAc shell infusion of ArIB in NIC or
CUEonly rats. *Significantly different from NIC vehicle infusion (po0.05).
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suggest that some individuals may have a shared vulner-
ability for tobacco dependence and schizophrenia pheno-
type. An accumulation of data indicates that a7 nAChR
expression is compromised in several brain areas of those
diagnosed with schizophrenia (Freedman et al, 1997, 2000;
Guan et al, 1999; Marutle et al, 2001). This phenotype seems
to be due to faulty receptor assembly or trafficking as
cigarette smoking results in elevated a7 nAChR message
and protein yet surface a7 nAChRs are decreased as
measured by a-bungarotoxin binding (Mexal et al, 2010).
This could be due to post-translational changes such as
reduced palmitoylation of the a7 nAChRs (Drisdel et al,
2004; Alexander et al, 2010) and further exacerbated in
individuals with a truncated, duplicate a7 nAChR gene
polymorphism that seems to lead to the formation of faulty
a7 nAChRs (Araud et al, 2011; de Lucas-Cerrillo et al, 2011).
Other studies suggest that a CHRNA7 intron dinucleotide
repeat is positively associated with a significant risk for
smoking behavior in those with schizophrenia (De Luca
et al, 2004) with evidence for marginal associations for
smoking risk in ‘healthy’ individuals with other point
mutations within the CHRNA7 gene (Saccone et al, 2010).
These studies in rodents give biological credence to these
genetic studies, demonstrating that reductions in a7 nAChR
function result in significant elevations in motivation to
self-administer NIC.
Although there may be some neuroanatomical overlap
with a7 nAChR-associated sensory-gating abnormalities, it
is likely that a7 nAChR deficits regulate smoking and
schizophrenia phenotype through different neuroanatomi-
cal pathways. The a7 nAChRs are enriched in deep layers of
the cortex that are connected to the sensory thalamus,
perhaps accounting for the sensory-gating deficits that are
associated with this genotype (Clarke et al, 1985; Luntz-
Leybman et al, 1992; Stevens et al, 1996; Breese et al, 1997;
Freedman et al, 1997; Bodnar et al, 2005; Hajos et al, 2005;
Leonard et al, 2007). a-Bungarotoxin-binding studies show
that a7 nAChR expression is higher in the cingulate and
more ubiquitously expressed across layers than in other
cortical regions (Marutle et al, 2001). Individuals diagnosed
with schizophrenia have a 50% reduction in cingulate
expression of a7 nAChRs (Marutle et al, 2001). We observed
that antagonism of a7 nAChRs in the anterior cingulate
cortex was sufficient to increase motivation to self-
administer NIC. Human studies have revealed that deficits
in prefrontal cortex function are also correlated with failed
quit attempts in schizophrenic smokers (Moss et al, 2009).
We saw a similar effect of blocking a7 nAChRs in the NAc
shell; local administration of an a7 nAChR antagonist
significantly increased NIC self-administration during PR.
In contrast, application of an a7 nAChR agonist effectively
reduced NIC administration but only when administered
into the NAc shell, perhaps due to the unique influence of
dopamine signaling on a7 nAChR activity at this locus vs
the predominant basal ganglia innervation that supports
activation of a7 nAChRs in the anterior cingulate cortex
(Thomsen et al, 2010). These findings warrant further study
into the expression of a7 nAChRs in the NAc shell of
smokers and in individuals diagnosed with schizophrenia.
Previous preclinical studies exploring the role of a7
nAChRs in NIC reinforcement have returned equivocal
results. Systemic administration of the a7 antagonist
methylcoconitine (MLA) resulted in significant reductions
in self-administration of NIC during an FR1 schedule of
reinforcement (Markou and Paterson, 2001) at 3.8 and
7.9mg/kg MLA, whereas others have reported no effect of a
similar dosing regimen on self-administration when rats
had a 2 day wash-out period between MLA dosings
(Grottick et al, 2000). Although it is not clear what
concentrations would be achieved in the brain at these
doses, in vitro studies have shown that higher concentra-
tions of MLA antagonize a6*nAChRs (Mogg et al, 2002), as
well as a7 nAChRs. Recent reports show that activation of
a6*nAChRs in the VTA and NAc shell are critical for
acquisition and maintenance of NIC self-administration
(Pons et al, 2008; Brunzell et al, 2010; Gotti et al, 2010);
thus, effects with high doses of MLA may have been due to
off-target antagonism of a6*nAChRs. The ArIB compound
used in this study has 4500-fold selectivity for a7 nAChRs
over other nAChR subtypes (Whiteaker et al, 2008). In
contrast, a-conotoxin MII is an antagonist of a6b2*
nAChRs. NAc infusion of MII using the same paradigm as
that used in this study shows the reverse effect of ArIB. That
is, blockade of a6b2*nAChRs by a-conotoxin MII dose
dependently decreased breakpoints and number of infu-
sions earned (Brunzell et al, 2010), whereas antagonism of
a7 nAChRs by ArIB increased NIC self-administration
during PR, a schedule of reinforcement that is considered to
measure motivation to self-administer drugs of abuse
(Arnold and Roberts, 1997). Moreover, in contrast to effects
of ArIB, we further observed that local administration of a
selective a7 nAChR agonist into the NAc shell decreased
NIC self-administration during PR. Thus, a6b2*nAChRs
and a7 nAChRs in the NAc shell seem to have an
opposing effect on NIC self-administration. Activation of
a6b2*nAChRs supports NIC self-administration, whereas
activation of a7 nAChRs impedes motivation to
self-administer the drug.
Figure 4 Neuroanatomical reconstructions of guide cannulae placement
in the NAc shell and anterior cingulate cortex.
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administration, our findings suggest that a7 nAChRs
modulate NIC administration behavior. This hypothesis is
supported by studies that show that mice with a7 subunit
null mutations show normal NIC reward as measured by
NIC conditioned place preference and acquisition of tail vein
NIC administration (Walters et al, 2006; Pons et al, 2008).
Other reports suggest that a7 may contribute to NIC intake
after repeated exposure as measured by a reduction in
NIC:water ratio during a 2-bottle choice paradigm (Levin
et al, 2009). However, it is not clear in these latter studies if
mice favor less NIC over time, or if over time, a7 knockout
mice need less drug to achieve the desired effects of NIC.
Our studies performed during PR indicate that local
antagonism of a7 nAChRs in the NAc shell and anterior
cingulate cortex increased the motivation of rats to work for
an intravenous NIC reinforcer. Given the low affinity of the
a7 nAChRs for NIC and the limited number of NIC infusions
achieved during the demanding PR schedule of reinforce-
ment, it is likely that the effect of ArIB was due to blockade
of an endogenous cholinergic signal and not due to blockade
of NIC action at a7 nAChRs (McGehee and Role, 1995;
Mansvelder et al, 2002; Wooltorton et al, 2003; Papke et al,
2010). Unlike the high-affinity b2*nAChRs, activation of a7
nAChRs on DA terminals is not critical for NIC-stimulated
striatal DA release (Champtiaux and Changeux, 2004;
Salminen et al, 2004), and a recent microdialysis study
showed that systemic administration of NIC results in
elevated, persistent release of DA in the NAc shell of a7
nAChR knockout mice compared with wild-type mice on the
same background (Besson et al, 2011). Hence, ACh activity
at a7 nAChRs in the NAc shell and anterior cingulate cortex
may curb NIC self-administration behavior through modula-
tion of DA release. These findings have implications for
individuals with schizophrenia who have a poverty of a7
nAChRs in the cingulate cortex (Marutle et al, 2001) that
may render them vulnerable to heavy tobacco use. Whereas
these findings resemble recent reports showing that
a5 nAChR subunit knockout mice administer more NIC
than their wild-type counterparts during FR schedules of
reinforcement (Fowler et al, 2011), we make a distinction
that the present observations do not reflect a decrease in the
aversive effects of NIC after a7 nAChR antagonism. In
general, NIC becomes aversive at high doses. During PR, rats
in this study received approximately one-third of the NIC
that they demonstrated they were willing to ingest during the
FR1 schedule of reinforcement (Table 1).
It appears from our studies that activation of a7 nAChRs
by the endogenous neurotransmitter ACh counters the
behavioral effects of NIC at the high-affinity nAChRs. It is
not clear whether most smokers achieve brain levels of NIC
that are sufficient to activate the lower-affinity a7 nAChRs,
but recent work using a
11C NIC tracer estimates that heavy
smokers, such as those with schizophrenia (de Leon, 1996),
may achieve as high as 700nM NIC in the brain after a
smoking episode and that brain levels of NIC accumulate
during the day (Rose et al, 2010). In vitro studies suggest
that 1–10mM NIC is sufficient to bind and activate a7
nAChRs and quickly after activation by NIC, nAChRs
undergo a period of desensitization (Lester and Dani, 1995;
McGehee et al, 1995; Mansvelder et al, 2002; Uteshev et al,
2002; Wooltorton et al, 2003; Papke et al, 2009). These
findings suggest that motivation to self-administer NIC
could be significantly elevated by desensitization of a7
nAChRs in the NAc shell or anterior cingulate cortex. This
effect could be exaggerated in schizophrenic smokers who
already have a deficit of a7 nAChRs in the cingulate cortex
(Marutle et al, 2001).
Recent studies have identified a7 nAChRs as therapeutic
targets for improving cognition, memory, and gating
deficits in schizophrenia (Bodnar et al, 2005; Olincy et al,
2006; Bitner et al, 2007; Freedman et al, 2008; Rezvani et al,
2009; Hajos and Rogers, 2010; Marquis et al, 2011). This
study in rats suggests that activation of a7 nAChRs may
have the added benefit of curbing motivation to smoke
cigarettes. It is of interest to note that the US Food and
Drug Administration approved smoking cessation drug,
varenicline, although marketed as an a4b2 nAChR partial
agonist, also has full agonist properties at a7 nAChRs
(Mihalak et al, 2006). The findings of this study suggest that
varenicline may exert some of its therapeutic effects
through activation of a7 nAChRs.
In summary, these data demonstrate that reductions in a7
nAChR function promote NIC use. These findings expand
on previous data which suggest that the CHRNA7 genotype
is associated with tobacco dependence and identify low
expression of a7 nAChRs as a potential mechanism by
which individuals express a shared vulnerability to tobacco
use and schizophrenia. These findings further identify
activation of a7 nAChRs as a strategy that should be further
explored for treatment of tobacco addiction.
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